312 related articles for article (PubMed ID: 30972011)
1. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A
Front Neurol; 2019; 10():280. PubMed ID: 30972011
[No Abstract] [Full Text] [Related]
2. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
3. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
Front Neurol; 2020; 11():608. PubMed ID: 32765393
[No Abstract] [Full Text] [Related]
4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
5. CSF chitinase 3-like-1 association with disability of primary progressive MS.
Pérez-Miralles F; Prefasi D; García-Merino A; Gascón-Giménez F; Medrano N; Castillo-Villalba J; Cubas L; Alcalá C; Gil-Perotín S; Gómez-Ballesteros R; Maurino J; Álvarez-García E; Casanova B
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32611760
[TBL] [Abstract][Full Text] [Related]
6. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
Front Neurol; 2019; 10():1008. PubMed ID: 31608004
[No Abstract] [Full Text] [Related]
7. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
[TBL] [Abstract][Full Text] [Related]
9. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
10. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
[TBL] [Abstract][Full Text] [Related]
11. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
12. CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration.
Pawlitzki M; Schreiber S; Bittner D; Kreipe J; Leypoldt F; Rupprecht K; Carare RO; Meuth SG; Vielhaber S; Körtvélyessy P
Front Neurol; 2018; 9():1037. PubMed ID: 30631300
[No Abstract] [Full Text] [Related]
13. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
Cross AH; Gelfand JM; Thebault S; Bennett JL; von Büdingen HC; Cameron B; Carruthers R; Edwards K; Fallis R; Gerstein R; Giacomini PS; Greenberg B; Hafler DA; Ionete C; Kaunzner UW; Kodama L; Lock C; Longbrake EE; Musch B; Pardo G; Piehl F; Weber MS; Yuen S; Ziemssen T; Bose G; Freedman MS; Anania VG; Ramesh A; Winger RC; Jia X; Herman A; Harp C; Bar-Or A
JAMA Neurol; 2024 Mar; 81(4):373-83. PubMed ID: 38466277
[TBL] [Abstract][Full Text] [Related]
14. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis.
Momtazmanesh S; Shobeiri P; Saghazadeh A; Teunissen CE; Burman J; Szalardy L; Klivenyi P; Bartos A; Fernandes A; Rezaei N
Rev Neurosci; 2021 Aug; 32(6):573-595. PubMed ID: 33594840
[TBL] [Abstract][Full Text] [Related]
15. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
Kessler C; Ruschil C; Abdelhak A; Wilke C; Maleska A; Kuhle J; Krumbholz M; Kowarik MC; Schüle R
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362248
[TBL] [Abstract][Full Text] [Related]
16. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
[TBL] [Abstract][Full Text] [Related]
17. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
[TBL] [Abstract][Full Text] [Related]
18. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
